A phase II trial to evaluate a neuroblastoma vaccine in patients with childhood neuroblastoma.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2015
Price : $35 *
At a glance
- Drugs Neuroblastoma vaccine (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 01 Dec 2015 Planned initiation date changed from 1 Jan 2015 to 1 Jan 2016, as per MabVax media release.
- 04 Feb 2015 According to MabVax media release, company received an Orphan Drug Designation from FDA in Sept 2014.
- 06 Jun 2014 New trial record